Reverse hydroxamate-based selective TACE inhibitors

被引：30

作者：

Kamei, N ^{[1
]}

Tanaka, T ^{[1
]}

Kawai, K ^{[1
]}

Miyawaki, K ^{[1
]}

Okuyama, A ^{[1
]}

Murakami, Y ^{[1
]}

Arakawa, Y ^{[1
]}

Haino, M ^{[1
]}

Harada, T ^{[1
]}

Shimano, M ^{[1
]}

机构：

[1] Kaken Pharmaceut Co Ltd, Yamashina Ku, Kyoto 6078042, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 11期

关键词：

D O I：

10.1016/j.bmcl.2004.03.048

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Reverse hydroxamate-based selective TACE inhibitors are described. They have potent TACE inhibitory activities and excellent selectivities against MMP-1, 2, 3, 8, 9, 13, 14, and 17. One representative compound, 18 has demonstrated an excellent oral inhibitory activity of the lipopolysaccharide (LPS)-stimulated TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：2897 / 2900

页数：4

共 37 条

[11] Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-α converting enzyme inhibitors [J].

Letavic, MA ;

Barberia, JT ;

Carty, TJ ;

Hardink, JR ;

Liras, J ;

Lopresti-Morrow, LL ;

Mitchell, PG ;

Noe, MC ;

Reeves, LM ;

Snow, SL ;

Stam, EJ ;

Sweeney, FJ ;

Vaughn, ML ;

Yu, CH .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (19) :3243-3246

[12] Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates [J].

Levin, JI ;

Chen, JM ;

Cheung, K ;

Cole, D ;

Crago, C ;

Santos, ED ;

Du, X ;

Khafizova, G ;

MacEwan, G ;

Niu, C ;

Salaski, EJ ;

Zask, A ;

Cummons, T ;

Sung, A ;

Xu, J ;

Zhang, Y ;

Xu, W ;

Ayral-Kaloustian, S ;

Jin, G ;

Cowling, R ;

Barone, D ;

Mohler, KM ;

Black, RA ;

Skotnicki, JS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) :2799-2803

[13]

LIST AF, 2002, 44 ANN M AM SOC HEM, P100

[14] Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme [J].

Maskos, K ;

Fernandez-Catalan, C ;

Huber, R ;

Bourenkov, GP ;

Bartunik, H ;

Ellestad, GA ;

Reddy, P ;

Wolfson, MF ;

Rauch, CT ;

Castner, BJ ;

Davis, R ;

Clarke, HRG ;

Petersen, M ;

Fitzner, JN ;

Cerretti, DP ;

March, CJ ;

Paxton, RJ ;

Black, RA ;

Bode, W .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3408-3412

[15] Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers [J].

Matsumoto, M ;

Mariathasan, S ;

Nahm, MH ;

Baranyay, F ;

Peschon, JJ ;

Chaplin, DD .

SCIENCE, 1996, 271 (5253) :1289-1291

[16] Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial [J].

Mease, PJ ;

Goffe, BS ;

Metz, J ;

VanderStoep, A ;

Finck, B ;

Burge, DJ .

LANCET, 2000, 356 (9227) :385-390

[17] Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors [J].

Moriyama, H ;

Tsukida, T ;

Inoue, Y ;

Kondo, H ;

Yoshino, K ;

Nishimura, SI .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) :2741-2744

[18] Structure-activity relationships of azasugar-based MMP/ADAM inhibitors [J].

Moriyama, H ;

Tsukida, T ;

Inoue, Y ;

Kondo, H ;

Yoshino, K ;

Nishimura, SI .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) :2737-2740

[19] Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha [J].

Moss, ML ;

Jin, SLC ;

Milla, ME ;

Burkhart, W ;

Carter, HL ;

Chen, WJ ;

Clay, WC ;

Didsbury, JR ;

Hassler, D ;

Hoffman, CR ;

Kost, TA ;

Lambert, MH ;

Leesnitzer, MA ;

McCauley, P ;

McGeehan, G ;

Mitchell, J ;

Moyer, M ;

Pahel, G ;

Rocque, W ;

Overton, LK ;

Schoenen, F ;

Seaton, T ;

Su, JL ;

Warner, J ;

Willard, D ;

Becherer, JD .

NATURE, 1997, 385 (6618) :733-736

[20] TACE and other ADAM proteases as targets for drug discovery [J].

Moss, ML ;

White, JM ;

Lambert, MH ;

Andrews, RC .

DRUG DISCOVERY TODAY, 2001, 6 (08) :417-426

← 1 2 3 4 →